Cannabinoids for the treatment of neuropathic pain: Clinical evidence.

Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Abstract Text:

John C Ashton,Erin D Milligan,John C Ashton,Erin D Milligan,

Neuropathic pain is a worldwide epidemic that occurs in 3 to 8% of individuals in industrialized countries and is often refractory to existing treatments. Drugs currently available to target neuropathic pain are, at best, moderately effective and include antidepressants, gabapentin, NMDA receptor antagonists, as well as other anticonvulsants, all of which are limited by their adverse-effect profiles. Cannabinoid drugs are emerging as a promising class of drugs to treat neuropathic pain and have been tested for analgesic effects in a range of chronic pain conditions. Data show that cannabinoids are often effective in individuals with refractory pain receiving concomitant analgesic drugs. Clinical studies on cannabinoids for the treatment of neuropathic pain are reviewed, focusing on clinical trials published within the last five years. Data from large, well-controlled studies show that cannabinoids are moderately effective in reducing chronic pain and that side effects are comparable to existing treatments, suggesting that cannabinoids can play a useful role in the management of chronic pain. Like other drugs for neuropathic pain, cannabinoids have a dose titration that is limited by psychoactive side effects. The development of cannabinoid drugs to target neuropathic pain with improved therapeutic ratios will depend upon the development of cannabinoid treatments with reduced psychoactivity.

Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Publishing Authors By Initials

JC Ashton,ED Milligan,JC Ashton,ED Milligan,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current opinion in investigational drugs (London,

VOLUME: 9

Page Numbers: 65-75

Journal Abbreviation:

ISSN: 1472-4472

DAY: 9

MONTH: Jan

YEAR: 2008

Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100965718

Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cannabinoids for the treatment of neuropathic pain: Clinical evidence. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cannabinoids for the treatment of neuropathic pain: Clinical evidence.

AFFILIATION: University of Otago, Otago School of Medical Sciences, Department of Pharmacology and Toxicology, PO Box 913, Dunedin 9054, New Zealand. Email: john.ashton@stonebow.otago.ac.nz.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Opin Investig Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cannabinoids for the treatment of neuropathic pain: Clinical evidence Related Publications

• A simple approach to test for interaction between intervention and an individual-level variable in community randomized trials.
• An instrument to level tissue in paraffin embedding.
• Analysis of the weak interactions of ADP-Unc104 and ADP-kinesin with microtubules and their inhibition by MAP2c.
• Antibodies that identify only the active conformation of Gi family G protein {alpha} subunits.
• Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.
• Astrocyte and muscle-derived secreted factors differentially regulate motoneuron survival.
• CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.
• Cannabinoids for the treatment of neuropathic pain: Clinical evidence.
• Chemical methods in the evaluation of human contamination.
• Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors.
• Early resolution of herpes simplex virus type 2 infection of the murine genital tract involves stimulation of genital parenchymal cells by gamma interferon.
• Epizootiology of trypanosomiases: some aspects of mathematical modelling.
• Exogenous Hsc70, but not thermal preconditioning, confers protection to motoneurons subjected to oxidative stress.
• G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors.
• G-protein-coupled receptors: an update.
• In vitro methods to prepare astrocyte and motoneuron cultures for the investigation of potential in vivo interactions.
• Lucky 13-microtubule depolymerisation by kinesin-13 motors.
• Mallory-Weiss syndrome with esophageal obstruction secondary to adherent intraluminal thrombus.
• Maternal employment, breastfeeding, and health: Evidence from maternity leave mandates.
• Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta(2)-adrenoceptor and the ERK1/2 MAPKs: implications for beta(2)-adrenoceptor signalling via the ERK1/2 MAPKs.
• New aspects of g-protein-coupled receptor signalling and regulation.
• Reactivity of DNA guanyl radicals with phenolate anions.
• Regulation of heat shock protein 70 release in astrocytes: role of signaling kinases.
• Some determinants of attrition in prospective studies on aging.
• The patient's point of view.
• Treatment of psychoneurosis; modified CO2 abreactive technique.
• Urology in a modern health centre.
• Visualisation of a kinesin-13 motor on microtubule end mimics.
• Warburg (HARD +/- E) syndrome without retinal dysplasia: case report and review.
• c-Jun N-terminal kinase signaling regulates events associated with both health and degeneration in motoneurons.